Reviewing Arrowhead Pharmaceuticals Inc. (ARWR)’s and Its Peers results

We are comparing Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) and its competitors on their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation. They are Biotechnology companies, competing one another.

Insider & Institutional Ownership

63.8% of Arrowhead Pharmaceuticals Inc.’s shares are owned by institutional investors. Comparatively, 53.20% of all Biotechnology’s companies shares are owned by institutional investors. On other hand Arrowhead Pharmaceuticals Inc. has 3.7% of its shares owned by company insiders versus an average of 8.45% insiders ownership for its competitors.


Table 1 has Arrowhead Pharmaceuticals Inc. and its competitors’ return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Arrowhead Pharmaceuticals Inc. 202,914,310.57% 6.70% 4.30%
Industry Average 812.10% 105.95% 28.39%

Valuation and Earnings

The following data compares Arrowhead Pharmaceuticals Inc. and its competitors’ valuation, top-line revenue and net income.

Net Income Gross Revenue Price/Earnings Ratio
Arrowhead Pharmaceuticals Inc. 93.30M 46 398.08
Industry Average 33.76M 4.16M 35.97

Arrowhead Pharmaceuticals Inc. has lower revenue, but higher P/E Ratio than its competitors. The business has a higher price-to-earnings ratio which is currently more expensive in contrast to its competitors.

Analyst Recommendations

Table 3 shows breakdown of recent ratings for Arrowhead Pharmaceuticals Inc. and its competitors.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Arrowhead Pharmaceuticals Inc. 0 1 5 2.83
Industry Average 1.10 1.78 2.38 2.81

$54 is the consensus target price of Arrowhead Pharmaceuticals Inc., with a potential downside of -15.63%. The competitors have a potential upside of 168.19%. Given Arrowhead Pharmaceuticals Inc.’s stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals Inc. is more favorable than its competitors.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Arrowhead Pharmaceuticals Inc. and its competitors.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Arrowhead Pharmaceuticals Inc. -0.58% 9.7% 66.72% 113.36% 107.57% 133.98%
Industry Average 5.82% 9.20% 28.08% 41.63% 73.35% 54.83%

For the past year Arrowhead Pharmaceuticals Inc. was more bullish than its competitors.


The Current Ratio and a Quick Ratio of Arrowhead Pharmaceuticals Inc. are 2.3 and 2.3. Competitively, Arrowhead Pharmaceuticals Inc.’s competitors have 7.07 and 6.86 for Current and Quick Ratio. Arrowhead Pharmaceuticals Inc.’s peers have better ability to pay short and long-term obligations than Arrowhead Pharmaceuticals Inc.

Volatility and Risk

Arrowhead Pharmaceuticals Inc. is 58.00% more volatile than S&P 500 because the stock has a beta of 1.58. Competitively, Arrowhead Pharmaceuticals Inc.’s competitors’ beta is 1.77 which is 76.75% more volatile than S&P 500.


Arrowhead Pharmaceuticals Inc. does not pay a dividend.


Arrowhead Pharmaceuticals Inc. shows that it’s better in 4 of the 6 factors compared to Arrowhead Pharmaceuticals Inc.’s peers.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.